IL-10 induces CCR6 expression during Langerhans cell development while IL-4 and IFN-gamma suppress it.
Immune responses are initiated by dendritic cells (DC) that form a network comprising different populations. In particular, Langerhans cells (LC) appear as a unique population of cells colonizing epithelial surfaces. We have recently shown that macrophage-inflammatory protein-3alpha/CCL20, a chemokine secreted by epithelial cells, induces the selective migration of LC among DC populations. In this study, we investigated the effects of cytokines on the expression of the CCL20 receptor, CCR6, during differentiation of LC. We found that both IL-4 and IFN-gamma blocked the expression of CCR6 and CCL20 responsiveness at different stages of LC development. The effect of IL-4 was reversible and most likely due to the transient blockade of LC differentiation. In contrast, IFN-gamma-induced CCR6 loss was irreversible and was concomitant to the induction of DC maturation. When other cytokines involved in DC and T cell differentiation were tested, we found that IL-10, unlike IL-4 and IFN-gamma, maintained CCR6 expression. The effect of IL-10 was reversible and upon IL-10 withdrawn, CCR6 was lost concomitantly to final LC differentiation. In addition, IL-10 induced the expression of CCR6 and responsiveness to CCL20 in differentiated monocytes that preserve their ability to differentiate into mature DC. Finally, TGF-beta, which induces LC differentiation, did not alter early CCR6 expression, but triggered its irreversible down-regulation, in parallel to terminal LC differentiation. Taken together, these results suggest that the recruitment of LC at epithelial surface might be suppressed during Th1 and Th2 immune responses, and amplified during regulatory immune responses involving IL-10 and TGF-beta.
Dieu-Nosjean
M C
MC
Laboratory of Cellular and Clinical Immunology, Institut National de la Santé et de la Recherche Médicale Unité 255, Institut de Recherches Biomédicales des Cordeliers, Paris, France. mc.dieu-nosjean@u255.bhdc.jussieu.fr
Massacrier
C
C
Vanbervliet
B
B
Fridman
W H
WH
Caux
C
C
D018952:Antigens, CD34 / Q000032:analysis; D002454:Cell Differentiation; D002460:Cell Line; D002478:Cells, Cultured; D054418:Chemokine CCL20; D019742:Chemokines, CC / Q000494:pharmacology; D002633:Chemotaxis / Q000187:drug effects; D006801:Humans; D007371:Interferon-gamma / Q000494:pharmacology*; D016753:Interleukin-10 / Q000494:pharmacology*; D015847:Interleukin-4 / Q000494:pharmacology*; D007801:Langerhans Cells / Q000276:immunology*; D019402:Macrophage Inflammatory Proteins / Q000494:pharmacology; D009000:Monocytes / Q000276:immunology; D054399:Receptors, CCR6; D019707:Receptors, Chemokine / Q000096:biosynthesis*; D013234:Stem Cells / Q000276:immunology; D016212:Transforming Growth Factor beta / Q000494:pharmacology; D015854:Up-Regulation
D018952:Antigens, CD34; C108355:CCL20 protein, human; C106311:CCR6 protein, human; D054418:Chemokine CCL20; D019742:Chemokines, CC; D019402:Macrophage Inflammatory Proteins; D054399:Receptors, CCR6; D019707:Receptors, Chemokine; D016212:Transforming Growth Factor beta; D016753:Interleukin-10; D015847:Interleukin-4; D007371:Interferon-gamma